The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease

Impellizzeri, Daniela; Bruschetta, Giuseppe; Paola, Rosanna Di; Ahmad, Akbar; Campolo, Michela; Cuzzocrea, Salvatore; Esposito, Emanuela; Navarra, Michele

doi:10.1016/j.clnu.2014.11.012

Cited by 103 publications

(94 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potency of MPO inhibition by F105 was further increased 14-fold over BFE alone, from 42 to 2.95 g/mL. A recent study demonstrated the ability of BFE to inhibit colonic MPO activity in the mouse colitis model (Impellizzeri et al 2015). In our own observational trial, ex vivo inhibition of MPO trended from −7.7% to −13% (p > 0.05), respectively, in subjects and subgroup.…”

Section: Discussionmentioning

confidence: 76%

“…While this fruit is primarily used in the fragrance industry for its essential oil extracted from its peel, recent studies on the juice from the endocarp of bergamot have shown that it has several bioactivities such as antioxidant, antiinflammatory, cytotoxic, neuroprotective, as well as hypolipidemic and hypoglycemic properties (Currò et al 2016;Impellizzeri et al 2015;Miceli et al 2007;Mollace et al 2008;Risitano et al 2014;Sicari et al 2016;Trovato et al 2010;Tundis et al 2012). From clinical and mechanistic studies, it has been proposed (Mollace et al 2011) that melitidine and brutieridine in concert with naringin and other flavonone glycosides might be responsible for the hypolipidemic effects of BFE and function as do the statin drugs through the direct action on 3-hydroxy-3-methyl-glutaryl -coenzyme A (HMG-CoA) reductase activity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation includingCitrus bergamia, in subjects with moderate cardiometabolic risk factors

Babish¹,

Dahlberg

et al. 2016

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Abstract:We examined the clinical safety and efficacy of F105 in 11 subjects with moderate dyslipidemia. F105 is a combination of bergamot fruit extract (Citrus bergamia, BFE) and 9 phytoextracts selected for their ability to improve the antioxidant and anti-inflammatory activity of BFE. In vitro F105 exhibited a synergistic inhibition of oxygen radical absorbing capacity, peroxynitrite formation, and myeloperoxidase activity. Following 12 weeks of F105 daily, no treatment-related adverse events or changes in body mass were seen. Statistically significant changes were noted in total cholesterol (−7.3%), LDL-cholesterol (−10%), non-HDL cholesterol (−7.1%), cholesterol/HDL (−26%), and apolipoprotein B (−2.8%). A post hoc analysis of 8 subjects with HbA1c > 5.4 and HOMA-IR score > 2 or elevated triglycerides revealed additional statistically significant changes in addition to those previously observed in all subjects including triglycerides (−27%), oxLDL (−19%), LDL/HDL (−25%), triglycerides/HDL (−27%), oxLDL/HDL (−25%), and PAI-1 (−37%). A follow-up case report of a 70-year-old female patient, nonresponsive to statin therapy and placed on F105 daily, demonstrated improved cardiometabolic variables over 12 weeks similar to the subgroup. In summary, F105 was clinically well-tolerated and effective for ameliorating dyslipidemia in subjects with moderate cardiometabolic risk factors, particularly in the individuals with HbA1c > 5.4%.Key words: cardiometabolic disease, bergamot, antioxidant, myeloperoxidase, oxidized LDL, dyslipidemia, HbA1c. Résumé :Les auteurs ont examiné la sécurité et l'efficacité cliniques du F105 chez 11 sujets présentant une dyslipidémie modérée. Le F105 est une combinaison d'extrait de bergamote (Citrus bergamia, EB) et 9 extraits végétaux sélectionnés pour leur capacité à améliorer l'activité antioxydante et anti-inflammatoire de l'EB. In vitro, le F105 montrait une inhibition synergique de la capacité d'absorption des radicaux d'oxygène, de formation de peroxynitrite et de l'activité myéloperoxydase. Après 12 semaines d'administration quotidienne de F105, aucun effet secondaire indésirable relié au traitement ou changements de poids corporels n'étaient observés. Des changements statistiquement significatifs ont été notés quant au cholestérol total (−7,3 %), LDL-cholestérol (−10 %), non-HDL-cholestérol (−7,1 %), cholestérol/HDL (−26 %) et apolipoprotéine B (−2,8 %). Une analyse post hoc de 8 sujets présentant une HbA1c > 5.4 et un indice HOMA-IR >2 ou des triglycérides élevés a révélé des changements additionnels statistiquement significatifs en plus de ceux précédemment observés chez tous les sujets incluant les triglycérides (−27 %), oxLDL (−19 %), LDL/HDL (−25 %) triglycérides/HDL (−27 %), oxLDL/HDL (−25 %), et PAI-1 (−37 %). Une étude de cas de suivi d'une patiente de 70 ans, ne répondant pas à la thérapie par les statines et traitée au F105 quotidiennement, a démontré amélioration des variables cardiométaboliques pendant les 12 semaines similaire au sous-groupe. En résumé, le F105 est bie...

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation includingCitrus bergamia, in subjects with moderate cardiometabolic risk factors

Babish¹,

Dahlberg

et al. 2016

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In addition, although natural remedies are not risk free, they are generally safer than both synthetic and biological drugs. In this context, we have recently shown that BJe has antioxidant properties [235,236] and is able to suppress pro-inflammatory responses in both in vitro [237,238] and in vivo models [239,240]. Interestingly, evidence showing that BJ did not significantly affect the viability of normal human diploid fibroblast WI-38 cells [229], as well as not provoking any apparent sign of systemic toxicity [231], together with its antimicrobial activity [241,242] and favorable safety/efficacy balance [243], reveals the potential of BJe as an anti-cancer remedy, highlighting that it could represent a novel strategic approach in oncology field.…”

Section: Anti-cancer Properties Of Citrus Juices and Extractsmentioning

confidence: 99%

Chemopreventive Agents and Inhibitors of Cancer Hallmarks: May Citrus Offer New Perspectives?

et al. 2016

Self Cite

View full text Add to dashboard Cite

Fruits and vegetables have long been recognized as potentially important in the prevention of cancer risk. Thus, scientific interest in nutrition and cancer has grown over time, as shown by increasing number of experimental studies about the relationship between diet and cancer development. This review attempts to provide an insight into the anti-cancer effects of Citrus fruits, with a focus on their bioactive compounds, elucidating the main cellular and molecular mechanisms through which they may protect against cancer. Scientific literature was selected for this review with the aim of collecting the relevant experimental evidence for the anti-cancer effects of Citrus fruits and their flavonoids. The findings discussed in this review strongly support their potential as anti-cancer agents, and may represent a scientific basis to develop nutraceuticals, food supplements, or complementary and alternative drugs in a context of a multi-target pharmacological strategy in the oncology.

show abstract

“…However, bergamot juice, obtained from the endocarp after essential oils extraction, has long time been considered just a secondary and discarded product of the essential oil industry due to its bitter taste. Recently, it gained attention because of its hypolipemic and hypoglycaemic activity (Mollace et al, 2011), as well as its anti-inflammatory (Impellizzeri et al, 2014; Risitano et al, 2014) and anti-cancer properties (Delle Monache et al, 2013; Navarra et al, 2014; Visalli et al, 2014). …”

Section: Introductionmentioning

confidence: 99%

Citrus bergamia essential oil: from basic research to clinical application

et al. 2015

Self Cite

View full text Add to dashboard Cite

Citrus bergamia Risso et Poiteau, also known as “Bergamot,” is a plant belonging to the Rutaceae family, defined as a hybrid of bitter orange and lemon. It is an endemic plant of the Calabria region (Italy). Bergamot fruit is primarily used for the extraction of its essential oil (bergamot essential oil: BEO), employed in perfume, cosmetics, food, and confections. The aim of this review was to collect recent data from the literature on C. bergamia essential oil and, through a critical analysis, focus on safety and the beneficial effects on human health. Clinical studies on the therapeutic applications of BEO exclusively focus on the field of aromatherapy, suggesting that its use can be useful for reducing anxiety and stress.

show abstract

The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease

Cited by 103 publications

References 28 publications

Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation includingCitrus bergamia, in subjects with moderate cardiometabolic risk factors

Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation includingCitrus bergamia, in subjects with moderate cardiometabolic risk factors

Chemopreventive Agents and Inhibitors of Cancer Hallmarks: May Citrus Offer New Perspectives?

Citrus bergamia essential oil: from basic research to clinical application

Contact Info

Product

Resources

About